Literature DB >> 8386107

Increased LTB4 metabolites and PGD2 in BAL fluid after methacholine challenge in asthmatic subjects.

D Nowak1, F Grimminger, R Jörres, M Oldigs, K F Rabe, W Seeger, H Magnussen.   

Abstract

The bronchoconstrictor potency of inhaled methacholine is widely used to assess airway responsiveness. However, evidence has accumulated that methacholine inhalation challenge may lead to an inflammatory response in the lower respiratory tract. We therefore compared cellular, leukotriene and prostanoid profiles in bronchoalveolar lavages (BAL) obtained five hours after methacholine challenge to control lavages without prior challenge. Eight subjects with asymptomatic to mild bronchial asthma and nine nonatopic healthy controls were enrolled in the study. Without prior challenge, the percentage of BAL eosinophils was higher in the asthmatic subjects ((mean +/- SD), 1.1 +/- 0.9%) than in the control subjects (0.1 +/- 0.1%. Leukotriene B4 (LTB4), and its omega-oxidation products (20-OH-LTB4 and 20-COOH-LTB4) were the only leukotrienes detectable in the baseline BAL fluids in five of the eight asthmatic patients. After methacholine challenge, no change in BAL cell profile occurred, but in the asthmatic patients, the total amounts of LTB4 and its omega-oxidation products rose from 0.52 +/- 0.50 ng.ml-1 (pre-challenge) to 1.55 +/- 1.32 ng.ml-1 (post-challenge), and prostaglandin D2 (PGD2) rose from 49.1 +/- 15.7 (pre-challenge) to 94.4 +/- 25.4 pg.ml-1 (post-challenge), with no change in 6-keto-PGF1 alpha, thromboxane B2 (TXB2), and prostaglandins F2 alpha and E2 (PGF2 alpha and PGE2). In the healthy controls, no consistent change in BAL cell profile and mediators occurred after methacholine provocation. We conclude that inhaled methacholine stimulates LTB4 and PGD2 release in asthmatics, but not in healthy controls, without affecting the number of inflammatory cells in BAL fluid.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386107

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma.

Authors:  J A Schmidt; F M Bell; E Akam; C Marshall; I A Dainty; A Heinemann; I G Dougall; R V Bonnert; C A Sargent
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

2.  Localized eosinophil degranulation mediates disease in tropical pulmonary eosinophilia.

Authors:  Laura O'Bryan; Paula Pinkston; V Kumaraswami; V Vijayan; Gordon Yenokida; Helene F Rosenberg; Ronald Crystal; Eric A Ottesen; Thomas B Nutman
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

3.  Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells.

Authors:  Luzheng Xue; Maryam Salimi; Isabel Panse; Jenny M Mjösberg; Andrew N J McKenzie; Hergen Spits; Paul Klenerman; Graham Ogg
Journal:  J Allergy Clin Immunol       Date:  2013-12-31       Impact factor: 10.793

4.  Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma.

Authors:  Marie-Chantal Larose; Anne-Sophie Archambault; Véronique Provost; Michel Laviolette; Nicolas Flamand
Journal:  Front Med (Lausanne)       Date:  2017-08-11

5.  The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism.

Authors:  Wentao Chen; Jian Luo; Yuan Ye; Ryan Hoyle; Wei Liu; Rowie Borst; Shamsah Kazani; Eric A Shikatani; Veit J Erpenbeck; Ian D Pavord; Paul Klenerman; David A Sandham; Luzheng Xue
Journal:  J Immunol       Date:  2021-05-19       Impact factor: 5.422

6.  Transcriptional Changes of Blood Eosinophils After Methacholine Inhalation Challenge in Asthmatics.

Authors:  Scott J Tebbutt; Jian-Qing He; Amrit Singh; Casey P Shannon; Jian Ruan; Chris Carlsten
Journal:  Genomics Insights       Date:  2012-01-30

7.  Human intrahepatic ILC2 are IL-13positive amphiregulinpositive and their frequency correlates with model of end stage liver disease score.

Authors:  Hannah C Jeffery; Patrick McDowell; Philipp Lutz; Rebecca E Wawman; Sheree Roberts; Chris Bagnall; Jane Birtwistle; David H Adams; Ye Htun Oo
Journal:  PLoS One       Date:  2017-12-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.